Xiamen Amoytop Biotech Co Ltd Cash Flow Conversion Efficiency
Xiamen Amoytop Biotech Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has a cash flow conversion efficiency ratio of 0.197x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥332.29 Million ≈ $48.63 Million USD) by net assets (CN¥1.69 Billion ≈ $247.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xiamen Amoytop Biotech Co Ltd (2016–2024)
Cash flow conversion efficiency of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. This chart illustrates how Xiamen Amoytop Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Xiamen Amoytop Biotech Co Ltd share price for real-time trading data and today's change.
Xiamen Amoytop Biotech Co Ltd Cash Flow Conversion Ratio Explained
Xiamen Amoytop Biotech Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xiamen Amoytop Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their cash flow conversion efficiency. Also see 688278 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CCC S.A.
WAR:CCC
|
0.290x |
|
Union Bank of Taiwan
TW:2838
|
-0.031x |
|
Braze Inc
NASDAQ:BRZE
|
0.040x |
|
Lagardere SCA
PA:MMB
|
0.943x |
|
ArcBest Corp
NASDAQ:ARCB
|
0.007x |
|
Indosat Tbk
JK:ISAT
|
0.164x |
|
Gold Road Resources Ltd
AU:GOR
|
0.122x |
|
Disc Medicine Inc.
NASDAQ:IRON
|
-0.069x |
Annual Cash Flow Conversion Efficiency for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. Review Xiamen Amoytop Biotech Co Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.55 Billion ≈ $373.63 Million |
CN¥430.63 Million ≈ $63.02 Million |
0.169x | -38.20% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.58 Million |
CN¥512.10 Million ≈ $74.94 Million |
0.273x | +5.78% |
| 2022-12-31 | CN¥1.41 Billion ≈ $205.98 Million |
CN¥363.16 Million ≈ $53.14 Million |
0.258x | +27.61% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.93 Million |
CN¥234.78 Million ≈ $34.36 Million |
0.202x | +118.40% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.39 Million |
CN¥92.61 Million ≈ $13.55 Million |
0.093x | -57.69% |
| 2019-12-31 | CN¥563.55 Million ≈ $82.47 Million |
CN¥123.30 Million ≈ $18.04 Million |
0.219x | +22.53% |
| 2018-12-31 | CN¥499.26 Million ≈ $73.06 Million |
CN¥89.15 Million ≈ $13.04 Million |
0.179x | +856.57% |
| 2017-12-31 | CN¥483.26 Million ≈ $70.72 Million |
CN¥-11.41 Million ≈ $-1.67 Million |
-0.024x | -126.59% |
| 2016-12-31 | CN¥478.09 Million ≈ $69.96 Million |
CN¥42.43 Million ≈ $6.21 Million |
0.089x | -- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.